Mylan gained 16% to $37.80 today, while the S&P 500 advanced 0.1% to 2537.74. Teva dropped 15% to $16.08. Mizuho's Irina Koffler explains that today's approval …
Mylan N.V. (MYL - Free Report) was a big mover last session, as the company saw its shares rise more than 16% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks …
Shares of the pharmaceutical firm Mylan (MYL) were surging over 16% in pre …
The generic drug that Mylan N.C. got approval for is Glatiramer Acetate Injection 40 mg/mL for 3-times-a-week injection. This is a generic version of Teva Pharmaceutical Industries Ltd (ADR)’s (NYSE:TEVA) Copaxone. Approval from the …
causing Mylan's stock to soar 16.2% and Teva's to plummet 14.6%. The FDA approved both a daily 20 mg/ml dose and a 40 mg/ml dose that can be administered three times a week. There is already a generic competitor for the daily dose …
Shares of Teva Pharmaceuticals, which makes the branded version of Copaxone, …
Mylan NV MYL, -1.38% shares plummeted 9.2% in premarket trade Wednesday after the company reported profit and revenue misses and announced 2017 financial guidance that was below consensus. Earnings for the latest quarter rose …
The treatment is Teva’s biggest product, and the 40-milligram format brought in $3.64 billion in the 12 months ended July 31, Mylan said in a statement announcing …
CytomX Therapeutics, Inc., (Nasdaq: CTMX) 36.8% HIGHER; Amgen (Nasdaq: …
Mylan NV’s (MYL) stock was up 15 percent in pre-market trading after the pharmaceutical company confirmed that the Food and Drug Administration (FDA) approved two doses of its generic drug used to treat relapsing forms of multiple …